In this study, novel rhodanine–piperazine hybrids were designed and synthesized as potential inhibitors of VEGFR, EGFR, and HER2 tyrosine kinases, with the aim of developing new anticancer agents targeting breast cancer. The gene discussed is EGFR; the disease is breast carcinoma.